Hepion Pharmaceuticals, Inc. Gains 43.06%

Tue 07 Jul 20 at 05:30 PM
Hepion Pharmaceuticals, Inc. Gains 43.06%

Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ) soared at $4.12, a gain of 43.1%. The stock got featured on our News Catalysts scanner on Tue 07 Jul 20 at 07:51 AM in the 'BIOTECH' category. From Mon 22 Jun 20, the stock recorded 55.56% Up Days and 40.00% Green Days

The stock spiked on Tue 23 Jun 20 at $3.3 with a volume of 6M+, and its share price has been moving sideways in recent weeks.

About Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ)

ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.

Get 50% Off Premium Subscription
$19.99 USD
Limited-Time Discount
Your price will remain at $9.99 USD after the discount period
$9.99 USD
Signup 7 Days Trial. No Credit Card Required!
Ever wanted to explore stocks that have recently spiked... stocks moving sideways... or other trends? You're in the right place! Check StockTreats features.